PriceTargets.com logo

Nutriband - NTRB Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $13.00
  • Forecasted Upside: 124.91%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$5.78 As of 04/1/2025 04:58 PM ET
▼ -0.35 (-5.71%)

This chart shows the closing price for NTRB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
FebMar$5.78Closing price on 04/01/25:
Get New Nutriband Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NTRB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NTRB

Analyst Price Target is $13.00
▲ +124.91% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Nutriband in the last 3 months. The average price target is $13.00, with a high forecast of $13.00 and a low forecast of $13.00. The average price target represents a 124.91% upside from the last price of $5.78.

This chart shows the closing price for NTRB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
3/246/249/2412/244/254/26$2.34$5.01$7.67$10$13Closing price on 04/01/25: $5.78High$13.00Average$13.00Low$13.00




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Nutriband.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/9/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/7/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/2/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2025

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/22/2025Noble FinancialInitiated CoverageOutperform$13.00
(Data available from 4/1/2020 forward)

News Sentiment Rating

1.92 (Strong Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/3/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/3/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/2/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/2/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/1/2025
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/31/2025
  • 1 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/2/2025
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/1/2025

Current Sentiment

  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

Nutriband logo
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Read More

Today's Range

Now: $5.78
Low: $5.60
High: $6.21

50 Day Range

MA: $7.07
Low: $5.78
High: $9.90

52 Week Range

Now: $5.78
Low: $3.20
High: $11.78

Volume

24,636 shs

Average Volume

76,510 shs

Market Capitalization

$64.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Nutriband?

The following sell-side analysts have issued stock ratings on Nutriband in the last twelve months: Noble Financial.
View the latest analyst ratings for NTRB.

What is the current price target for Nutriband?

0 Wall Street analysts have set twelve-month price targets for Nutriband in the last year. Their average twelve-month price target is $13.00, suggesting a possible upside of 124.9%. Noble Financial has the highest price target set, predicting NTRB will reach $13.00 in the next twelve months. Noble Financial has the lowest price target set, forecasting a price of $13.00 for Nutriband in the next year.
View the latest price targets for NTRB.

What is the current consensus analyst rating for Nutriband?

Nutriband currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NTRB will outperform the market and that investors should add to their positions of Nutriband.
View the latest ratings for NTRB.

What other companies compete with Nutriband?

Other companies that are similar to Nutriband include Pulmonx, Nyxoah, Nevro, AVITA Medical and Electromed. Learn More about companies similar to Nutriband.

How do I contact Nutriband's investor relations team?

The company's listed phone number is (407) 377-6695 and its investor relations email address is info@nutriband.com. The official website for Nutriband is nutriband.com. Learn More about contacing Nutriband investor relations.